MX2007011697A - Biomarcadores para eficacia de aliskiren como agente hipertensivo. - Google Patents
Biomarcadores para eficacia de aliskiren como agente hipertensivo.Info
- Publication number
- MX2007011697A MX2007011697A MX2007011697A MX2007011697A MX2007011697A MX 2007011697 A MX2007011697 A MX 2007011697A MX 2007011697 A MX2007011697 A MX 2007011697A MX 2007011697 A MX2007011697 A MX 2007011697A MX 2007011697 A MX2007011697 A MX 2007011697A
- Authority
- MX
- Mexico
- Prior art keywords
- gene
- person
- treatment
- aliskiren
- snp
- Prior art date
Links
- UXOWGYHJODZGMF-QORCZRPOSA-N Aliskiren Chemical compound COCCCOC1=CC(C[C@@H](C[C@H](N)[C@@H](O)C[C@@H](C(C)C)C(=O)NCC(C)(C)C(N)=O)C(C)C)=CC=C1OC UXOWGYHJODZGMF-QORCZRPOSA-N 0.000 title claims abstract description 90
- 229960004601 aliskiren Drugs 0.000 title claims abstract description 89
- 239000005555 hypertensive agent Substances 0.000 title claims description 9
- 239000000090 biomarker Substances 0.000 title claims description 6
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 127
- 238000011282 treatment Methods 0.000 claims abstract description 110
- 108090000882 Peptidyl-Dipeptidase A Proteins 0.000 claims abstract description 66
- UUUHXMGGBIUAPW-UHFFFAOYSA-N 1-[1-[2-[[5-amino-2-[[1-[5-(diaminomethylideneamino)-2-[[1-[3-(1h-indol-3-yl)-2-[(5-oxopyrrolidine-2-carbonyl)amino]propanoyl]pyrrolidine-2-carbonyl]amino]pentanoyl]pyrrolidine-2-carbonyl]amino]-5-oxopentanoyl]amino]-3-methylpentanoyl]pyrrolidine-2-carbon Chemical compound C1CCC(C(=O)N2C(CCC2)C(O)=O)N1C(=O)C(C(C)CC)NC(=O)C(CCC(N)=O)NC(=O)C1CCCN1C(=O)C(CCCN=C(N)N)NC(=O)C1CCCN1C(=O)C(CC=1C2=CC=CC=C2NC=1)NC(=O)C1CCC(=O)N1 UUUHXMGGBIUAPW-UHFFFAOYSA-N 0.000 claims abstract description 62
- 230000000694 effects Effects 0.000 claims abstract description 52
- 239000002220 antihypertensive agent Substances 0.000 claims abstract description 21
- 229940030600 antihypertensive agent Drugs 0.000 claims abstract description 20
- 230000035487 diastolic blood pressure Effects 0.000 claims abstract description 13
- 230000035488 systolic blood pressure Effects 0.000 claims abstract description 11
- 108010062475 Type 2 Angiotensin Receptor Proteins 0.000 claims abstract description 9
- 102000004270 Peptidyl-Dipeptidase A Human genes 0.000 claims abstract 15
- 238000000034 method Methods 0.000 claims description 118
- 239000002773 nucleotide Substances 0.000 claims description 59
- 125000003729 nucleotide group Chemical group 0.000 claims description 59
- 230000002068 genetic effect Effects 0.000 claims description 37
- 230000009467 reduction Effects 0.000 claims description 35
- 239000003814 drug Substances 0.000 claims description 23
- 206010020772 Hypertension Diseases 0.000 claims description 21
- 108091033319 polynucleotide Proteins 0.000 claims description 17
- 102000040430 polynucleotide Human genes 0.000 claims description 17
- 239000002157 polynucleotide Substances 0.000 claims description 17
- 229940079593 drug Drugs 0.000 claims description 16
- 108020003175 receptors Proteins 0.000 claims description 16
- 230000000276 sedentary effect Effects 0.000 claims description 12
- 101150116411 AGTR2 gene Proteins 0.000 claims description 10
- 102400000344 Angiotensin-1 Human genes 0.000 claims description 10
- 101800000734 Angiotensin-1 Proteins 0.000 claims description 10
- ORWYRWWVDCYOMK-HBZPZAIKSA-N angiotensin I Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CC(C)C)C(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@@H](N)CC(O)=O)C(C)C)C1=CC=C(O)C=C1 ORWYRWWVDCYOMK-HBZPZAIKSA-N 0.000 claims description 10
- 108050000824 Angiotensin II receptor Proteins 0.000 claims description 8
- 108090000790 Enzymes Proteins 0.000 claims description 8
- 206010071602 Genetic polymorphism Diseases 0.000 claims description 8
- 102000008873 Angiotensin II receptor Human genes 0.000 claims description 7
- 102000004190 Enzymes Human genes 0.000 claims description 7
- 238000002560 therapeutic procedure Methods 0.000 claims description 5
- 102000015427 Angiotensins Human genes 0.000 claims description 4
- 108010064733 Angiotensins Proteins 0.000 claims description 4
- 230000004043 responsiveness Effects 0.000 claims description 4
- 238000011161 development Methods 0.000 claims description 3
- 101150028074 2 gene Proteins 0.000 claims 1
- 238000004458 analytical method Methods 0.000 abstract description 49
- 239000000902 placebo Substances 0.000 abstract description 34
- 229940068196 placebo Drugs 0.000 abstract description 34
- 102000054765 polymorphisms of proteins Human genes 0.000 abstract description 31
- 230000002974 pharmacogenomic effect Effects 0.000 abstract description 22
- 230000036454 renin-angiotensin system Effects 0.000 abstract description 19
- 239000002947 C09CA04 - Irbesartan Substances 0.000 abstract description 17
- 229960002198 irbesartan Drugs 0.000 abstract description 17
- YCPOHTHPUREGFM-UHFFFAOYSA-N irbesartan Chemical compound O=C1N(CC=2C=CC(=CC=2)C=2C(=CC=CC=2)C=2[N]N=NN=2)C(CCCC)=NC21CCCC2 YCPOHTHPUREGFM-UHFFFAOYSA-N 0.000 abstract description 17
- 230000007423 decrease Effects 0.000 abstract description 12
- 230000007614 genetic variation Effects 0.000 abstract description 8
- 230000029865 regulation of blood pressure Effects 0.000 abstract description 7
- 102000025309 Type 2 Angiotensin Receptor Human genes 0.000 abstract 2
- 102000054766 genetic haplotypes Human genes 0.000 description 55
- 239000000523 sample Substances 0.000 description 54
- 102000004196 processed proteins & peptides Human genes 0.000 description 51
- 108090000765 processed proteins & peptides Proteins 0.000 description 51
- 102100030988 Angiotensin-converting enzyme Human genes 0.000 description 49
- 229920001184 polypeptide Polymers 0.000 description 45
- 230000004044 response Effects 0.000 description 45
- 238000012360 testing method Methods 0.000 description 45
- 108091034117 Oligonucleotide Proteins 0.000 description 40
- 108700028369 Alleles Proteins 0.000 description 38
- 102000004169 proteins and genes Human genes 0.000 description 37
- 150000007523 nucleic acids Chemical class 0.000 description 31
- 230000014509 gene expression Effects 0.000 description 29
- 238000004949 mass spectrometry Methods 0.000 description 29
- 108020004414 DNA Proteins 0.000 description 28
- 108020004999 messenger RNA Proteins 0.000 description 28
- 102100028255 Renin Human genes 0.000 description 27
- 102000039446 nucleic acids Human genes 0.000 description 26
- 108020004707 nucleic acids Proteins 0.000 description 26
- 238000001514 detection method Methods 0.000 description 25
- 238000003205 genotyping method Methods 0.000 description 24
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 21
- 108090000783 Renin Proteins 0.000 description 17
- 201000010099 disease Diseases 0.000 description 17
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 17
- 230000008878 coupling Effects 0.000 description 16
- 238000010168 coupling process Methods 0.000 description 16
- 238000005859 coupling reaction Methods 0.000 description 16
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 14
- 102100028452 Nitric oxide synthase, endothelial Human genes 0.000 description 14
- 239000003550 marker Substances 0.000 description 14
- 239000013615 primer Substances 0.000 description 14
- 101001124309 Homo sapiens Nitric oxide synthase, endothelial Proteins 0.000 description 13
- 101001128156 Homo sapiens Nanos homolog 3 Proteins 0.000 description 12
- 239000000203 mixture Substances 0.000 description 12
- 102000005962 receptors Human genes 0.000 description 12
- 102100028161 ATP-binding cassette sub-family C member 2 Human genes 0.000 description 11
- 101000579218 Homo sapiens Renin Proteins 0.000 description 11
- 108010066419 Multidrug Resistance-Associated Protein 2 Proteins 0.000 description 11
- 230000000875 corresponding effect Effects 0.000 description 11
- 239000012634 fragment Substances 0.000 description 11
- 238000005259 measurement Methods 0.000 description 11
- 210000001519 tissue Anatomy 0.000 description 11
- 239000003795 chemical substances by application Substances 0.000 description 10
- 150000001875 compounds Chemical class 0.000 description 10
- 238000003795 desorption Methods 0.000 description 10
- 238000009396 hybridization Methods 0.000 description 10
- 238000003199 nucleic acid amplification method Methods 0.000 description 10
- 210000002381 plasma Anatomy 0.000 description 10
- 230000003321 amplification Effects 0.000 description 9
- 210000004369 blood Anatomy 0.000 description 9
- 239000008280 blood Substances 0.000 description 9
- 230000036772 blood pressure Effects 0.000 description 9
- 210000004027 cell Anatomy 0.000 description 9
- 230000001419 dependent effect Effects 0.000 description 9
- 238000002405 diagnostic procedure Methods 0.000 description 9
- 239000011159 matrix material Substances 0.000 description 9
- 238000003752 polymerase chain reaction Methods 0.000 description 9
- 239000007787 solid Substances 0.000 description 9
- 230000001225 therapeutic effect Effects 0.000 description 9
- 101000635938 Homo sapiens Transforming growth factor beta-1 proprotein Proteins 0.000 description 8
- 102100030742 Transforming growth factor beta-1 proprotein Human genes 0.000 description 8
- 150000001413 amino acids Chemical group 0.000 description 8
- 238000013459 approach Methods 0.000 description 8
- 230000027455 binding Effects 0.000 description 8
- 239000004072 C09CA03 - Valsartan Substances 0.000 description 7
- 241001465754 Metazoa Species 0.000 description 7
- 108091028043 Nucleic acid sequence Proteins 0.000 description 7
- 239000012472 biological sample Substances 0.000 description 7
- 210000000349 chromosome Anatomy 0.000 description 7
- 239000002299 complementary DNA Substances 0.000 description 7
- 238000005516 engineering process Methods 0.000 description 7
- 230000001404 mediated effect Effects 0.000 description 7
- 230000008569 process Effects 0.000 description 7
- 238000013518 transcription Methods 0.000 description 7
- 230000035897 transcription Effects 0.000 description 7
- 229960004699 valsartan Drugs 0.000 description 7
- SJSNUMAYCRRIOM-QFIPXVFZSA-N valsartan Chemical compound C1=CC(CN(C(=O)CCCC)[C@@H](C(C)C)C(O)=O)=CC=C1C1=CC=CC=C1C1=NN=N[N]1 SJSNUMAYCRRIOM-QFIPXVFZSA-N 0.000 description 7
- 102100035765 Angiotensin-converting enzyme 2 Human genes 0.000 description 6
- 101001090919 Homo sapiens N-acylglucosamine 2-epimerase Proteins 0.000 description 6
- 102100034977 N-acylglucosamine 2-epimerase Human genes 0.000 description 6
- 238000013475 authorization Methods 0.000 description 6
- 230000008859 change Effects 0.000 description 6
- 230000000295 complement effect Effects 0.000 description 6
- 229940088598 enzyme Drugs 0.000 description 6
- 230000006870 function Effects 0.000 description 6
- 239000012071 phase Substances 0.000 description 6
- 108010009911 Cytochrome P-450 CYP11B2 Proteins 0.000 description 5
- 102100024329 Cytochrome P450 11B2, mitochondrial Human genes 0.000 description 5
- 101000690425 Homo sapiens Type-1 angiotensin II receptor Proteins 0.000 description 5
- 101000765743 Homo sapiens Type-1 angiotensin II receptor-associated protein Proteins 0.000 description 5
- 238000011529 RT qPCR Methods 0.000 description 5
- 102100026803 Type-1 angiotensin II receptor Human genes 0.000 description 5
- 102100026563 Type-1 angiotensin II receptor-associated protein Human genes 0.000 description 5
- 239000002253 acid Substances 0.000 description 5
- 150000007513 acids Chemical class 0.000 description 5
- 230000015572 biosynthetic process Effects 0.000 description 5
- 230000037396 body weight Effects 0.000 description 5
- 238000004364 calculation method Methods 0.000 description 5
- 238000006243 chemical reaction Methods 0.000 description 5
- 238000013461 design Methods 0.000 description 5
- 238000003745 diagnosis Methods 0.000 description 5
- 238000002372 labelling Methods 0.000 description 5
- 238000004519 manufacturing process Methods 0.000 description 5
- 230000035772 mutation Effects 0.000 description 5
- -1 polypropylene Polymers 0.000 description 5
- 238000009097 single-agent therapy Methods 0.000 description 5
- 241000894007 species Species 0.000 description 5
- 238000007619 statistical method Methods 0.000 description 5
- 101150100998 Ace gene Proteins 0.000 description 4
- 108090000975 Angiotensin-converting enzyme 2 Proteins 0.000 description 4
- JZUFKLXOESDKRF-UHFFFAOYSA-N Chlorothiazide Chemical compound C1=C(Cl)C(S(=O)(=O)N)=CC2=C1NCNS2(=O)=O JZUFKLXOESDKRF-UHFFFAOYSA-N 0.000 description 4
- 108020004705 Codon Proteins 0.000 description 4
- 102000053602 DNA Human genes 0.000 description 4
- 102000001708 Protein Isoforms Human genes 0.000 description 4
- 108010029485 Protein Isoforms Proteins 0.000 description 4
- 239000000427 antigen Substances 0.000 description 4
- 230000004071 biological effect Effects 0.000 description 4
- 210000001124 body fluid Anatomy 0.000 description 4
- 239000010839 body fluid Substances 0.000 description 4
- 238000010367 cloning Methods 0.000 description 4
- 230000036541 health Effects 0.000 description 4
- 229960002003 hydrochlorothiazide Drugs 0.000 description 4
- 238000007477 logistic regression Methods 0.000 description 4
- 238000012986 modification Methods 0.000 description 4
- 230000004048 modification Effects 0.000 description 4
- 239000002461 renin inhibitor Substances 0.000 description 4
- 238000011160 research Methods 0.000 description 4
- 102220120640 rs886042620 Human genes 0.000 description 4
- 230000011218 segmentation Effects 0.000 description 4
- 238000012163 sequencing technique Methods 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- 102000040650 (ribonucleotides)n+m Human genes 0.000 description 3
- 238000004252 FT/ICR mass spectrometry Methods 0.000 description 3
- 241000102542 Kara Species 0.000 description 3
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 3
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 3
- 239000000654 additive Substances 0.000 description 3
- 229940044025 aliskiren 300 mg Drugs 0.000 description 3
- 239000012491 analyte Substances 0.000 description 3
- 230000003276 anti-hypertensive effect Effects 0.000 description 3
- 102000036639 antigens Human genes 0.000 description 3
- 108091007433 antigens Proteins 0.000 description 3
- 238000012098 association analyses Methods 0.000 description 3
- 238000012093 association test Methods 0.000 description 3
- 230000033228 biological regulation Effects 0.000 description 3
- 238000004422 calculation algorithm Methods 0.000 description 3
- 230000001413 cellular effect Effects 0.000 description 3
- 238000012512 characterization method Methods 0.000 description 3
- 239000003153 chemical reaction reagent Substances 0.000 description 3
- 238000007796 conventional method Methods 0.000 description 3
- 238000003935 denaturing gradient gel electrophoresis Methods 0.000 description 3
- 239000012530 fluid Substances 0.000 description 3
- 238000001502 gel electrophoresis Methods 0.000 description 3
- 230000001631 hypertensive effect Effects 0.000 description 3
- 238000000338 in vitro Methods 0.000 description 3
- 210000003734 kidney Anatomy 0.000 description 3
- 238000007834 ligase chain reaction Methods 0.000 description 3
- 238000002493 microarray Methods 0.000 description 3
- 230000002265 prevention Effects 0.000 description 3
- 238000012545 processing Methods 0.000 description 3
- 230000002829 reductive effect Effects 0.000 description 3
- 229940086526 renin-inhibitors Drugs 0.000 description 3
- 230000010076 replication Effects 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 239000002904 solvent Substances 0.000 description 3
- 239000000758 substrate Substances 0.000 description 3
- 238000003786 synthesis reaction Methods 0.000 description 3
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 2
- 108091023043 Alu Element Proteins 0.000 description 2
- 102000004881 Angiotensinogen Human genes 0.000 description 2
- 108090001067 Angiotensinogen Proteins 0.000 description 2
- 101100497948 Caenorhabditis elegans cyn-1 gene Proteins 0.000 description 2
- 241000282472 Canis lupus familiaris Species 0.000 description 2
- 241000282693 Cercopithecidae Species 0.000 description 2
- 108091033380 Coding strand Proteins 0.000 description 2
- 108010015742 Cytochrome P-450 Enzyme System Proteins 0.000 description 2
- 102000003849 Cytochrome P450 Human genes 0.000 description 2
- 238000007399 DNA isolation Methods 0.000 description 2
- 101000929928 Homo sapiens Angiotensin-converting enzyme 2 Proteins 0.000 description 2
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 2
- 102000008394 Immunoglobulin Fragments Human genes 0.000 description 2
- 108010021625 Immunoglobulin Fragments Proteins 0.000 description 2
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 2
- 241000699670 Mus sp. Species 0.000 description 2
- 102000008300 Mutant Proteins Human genes 0.000 description 2
- 108010021466 Mutant Proteins Proteins 0.000 description 2
- 101001098066 Naja melanoleuca Basic phospholipase A2 1 Proteins 0.000 description 2
- MWUXSHHQAYIFBG-UHFFFAOYSA-N Nitric oxide Chemical compound O=[N] MWUXSHHQAYIFBG-UHFFFAOYSA-N 0.000 description 2
- 239000004698 Polyethylene Substances 0.000 description 2
- 238000002123 RNA extraction Methods 0.000 description 2
- 241000700159 Rattus Species 0.000 description 2
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 2
- 108010090804 Streptavidin Proteins 0.000 description 2
- 108091023045 Untranslated Region Proteins 0.000 description 2
- 206010047139 Vasoconstriction Diseases 0.000 description 2
- 230000009102 absorption Effects 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 229940044478 aliskiren 150 mg Drugs 0.000 description 2
- 238000000540 analysis of variance Methods 0.000 description 2
- 238000003491 array Methods 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 229920001222 biopolymer Polymers 0.000 description 2
- 229960002685 biotin Drugs 0.000 description 2
- 239000011616 biotin Substances 0.000 description 2
- 239000000969 carrier Substances 0.000 description 2
- 229920002678 cellulose Polymers 0.000 description 2
- 235000010980 cellulose Nutrition 0.000 description 2
- 230000002759 chromosomal effect Effects 0.000 description 2
- 230000002860 competitive effect Effects 0.000 description 2
- 238000004132 cross linking Methods 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- 238000001962 electrophoresis Methods 0.000 description 2
- 238000000132 electrospray ionisation Methods 0.000 description 2
- 210000003608 fece Anatomy 0.000 description 2
- 238000002866 fluorescence resonance energy transfer Methods 0.000 description 2
- 238000001943 fluorescence-activated cell sorting Methods 0.000 description 2
- 239000011521 glass Substances 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 150000002484 inorganic compounds Chemical class 0.000 description 2
- 229910010272 inorganic material Inorganic materials 0.000 description 2
- 230000003993 interaction Effects 0.000 description 2
- 238000005040 ion trap Methods 0.000 description 2
- 230000000670 limiting effect Effects 0.000 description 2
- 238000001819 mass spectrum Methods 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 238000001840 matrix-assisted laser desorption--ionisation time-of-flight mass spectrometry Methods 0.000 description 2
- 230000010534 mechanism of action Effects 0.000 description 2
- 238000002483 medication Methods 0.000 description 2
- 238000010369 molecular cloning Methods 0.000 description 2
- 238000012544 monitoring process Methods 0.000 description 2
- 238000002515 oligonucleotide synthesis Methods 0.000 description 2
- 238000005457 optimization Methods 0.000 description 2
- 150000002894 organic compounds Chemical class 0.000 description 2
- 230000036470 plasma concentration Effects 0.000 description 2
- 239000002243 precursor Substances 0.000 description 2
- 230000000069 prophylactic effect Effects 0.000 description 2
- 230000004952 protein activity Effects 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 102200121278 rs1799983 Human genes 0.000 description 2
- 102200042900 rs2273697 Human genes 0.000 description 2
- 102220068228 rs3740066 Human genes 0.000 description 2
- 102210007878 rs4329 Human genes 0.000 description 2
- 102220112496 rs4362 Human genes 0.000 description 2
- 102200018845 rs4364 Human genes 0.000 description 2
- 102200034228 rs4539 Human genes 0.000 description 2
- 102200034199 rs4544 Human genes 0.000 description 2
- 102200034206 rs4545 Human genes 0.000 description 2
- 102200091828 rs4762 Human genes 0.000 description 2
- 102220211860 rs891512 Human genes 0.000 description 2
- 125000003607 serino group Chemical group [H]N([H])[C@]([H])(C(=O)[*])C(O[H])([H])[H] 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- 239000011734 sodium Substances 0.000 description 2
- 229910052708 sodium Inorganic materials 0.000 description 2
- 238000004611 spectroscopical analysis Methods 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 238000013519 translation Methods 0.000 description 2
- 210000002700 urine Anatomy 0.000 description 2
- 229940030337 valsartan 320 mg Drugs 0.000 description 2
- 230000025033 vasoconstriction Effects 0.000 description 2
- 230000024883 vasodilation Effects 0.000 description 2
- 238000001262 western blot Methods 0.000 description 2
- ASWBNKHCZGQVJV-UHFFFAOYSA-N (3-hexadecanoyloxy-2-hydroxypropyl) 2-(trimethylazaniumyl)ethyl phosphate Chemical compound CCCCCCCCCCCCCCCC(=O)OCC(O)COP([O-])(=O)OCC[N+](C)(C)C ASWBNKHCZGQVJV-UHFFFAOYSA-N 0.000 description 1
- UFBJCMHMOXMLKC-UHFFFAOYSA-N 2,4-dinitrophenol Chemical compound OC1=CC=C([N+]([O-])=O)C=C1[N+]([O-])=O UFBJCMHMOXMLKC-UHFFFAOYSA-N 0.000 description 1
- PAWQVTBBRAZDMG-UHFFFAOYSA-N 2-(3-bromo-2-fluorophenyl)acetic acid Chemical compound OC(=O)CC1=CC=CC(Br)=C1F PAWQVTBBRAZDMG-UHFFFAOYSA-N 0.000 description 1
- UIYUUEDFAMZISF-FTBISJDPSA-N 6-chloro-1,1-dioxo-3,4-dihydro-2h-1$l^{6},2,4-benzothiadiazine-7-sulfonamide;(2s)-3-methyl-2-[pentanoyl-[[4-[2-(2h-tetrazol-5-yl)phenyl]phenyl]methyl]amino]butanoic acid Chemical compound C1=C(Cl)C(S(=O)(=O)N)=CC2=C1NCNS2(=O)=O.C1=CC(CN(C(=O)CCCC)[C@@H](C(C)C)C(O)=O)=CC=C1C1=CC=CC=C1C1=NNN=N1 UIYUUEDFAMZISF-FTBISJDPSA-N 0.000 description 1
- 239000005541 ACE inhibitor Substances 0.000 description 1
- 101150059573 AGTR1 gene Proteins 0.000 description 1
- RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 description 1
- PQSUYGKTWSAVDQ-ZVIOFETBSA-N Aldosterone Chemical compound C([C@@]1([C@@H](C(=O)CO)CC[C@H]1[C@@H]1CC2)C=O)[C@H](O)[C@@H]1[C@]1(C)C2=CC(=O)CC1 PQSUYGKTWSAVDQ-ZVIOFETBSA-N 0.000 description 1
- PQSUYGKTWSAVDQ-UHFFFAOYSA-N Aldosterone Natural products C1CC2C3CCC(C(=O)CO)C3(C=O)CC(O)C2C2(C)C1=CC(=O)CC2 PQSUYGKTWSAVDQ-UHFFFAOYSA-N 0.000 description 1
- 102000013142 Amylases Human genes 0.000 description 1
- 108010065511 Amylases Proteins 0.000 description 1
- 244000105975 Antidesma platyphyllum Species 0.000 description 1
- 206010003445 Ascites Diseases 0.000 description 1
- 241000193830 Bacillus <bacterium> Species 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 241000700198 Cavia Species 0.000 description 1
- 102000003858 Chymases Human genes 0.000 description 1
- 108090000227 Chymases Proteins 0.000 description 1
- 108700010070 Codon Usage Proteins 0.000 description 1
- 108020004635 Complementary DNA Proteins 0.000 description 1
- 241000186216 Corynebacterium Species 0.000 description 1
- 108020003215 DNA Probes Proteins 0.000 description 1
- 239000003155 DNA primer Substances 0.000 description 1
- 239000003298 DNA probe Substances 0.000 description 1
- 230000004568 DNA-binding Effects 0.000 description 1
- 108010014303 DNA-directed DNA polymerase Proteins 0.000 description 1
- 102000016928 DNA-directed DNA polymerase Human genes 0.000 description 1
- 229920002307 Dextran Polymers 0.000 description 1
- 101100050026 Enterobacteria phage T4 y01J gene Proteins 0.000 description 1
- 241000283086 Equidae Species 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- 208000007530 Essential hypertension Diseases 0.000 description 1
- 108700024394 Exon Proteins 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 102000002068 Glycopeptides Human genes 0.000 description 1
- 108010015899 Glycopeptides Proteins 0.000 description 1
- 108091027305 Heteroduplex Proteins 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 101000686231 Homo sapiens Ras-related GTP-binding protein C Proteins 0.000 description 1
- 102000009786 Immunoglobulin Constant Regions Human genes 0.000 description 1
- 108010009817 Immunoglobulin Constant Regions Proteins 0.000 description 1
- 208000026350 Inborn Genetic disease Diseases 0.000 description 1
- 102100034343 Integrase Human genes 0.000 description 1
- 108091092195 Intron Proteins 0.000 description 1
- 102000003960 Ligases Human genes 0.000 description 1
- 108090000364 Ligases Proteins 0.000 description 1
- 238000012563 MS-based analyses Methods 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 108091027974 Mature messenger RNA Proteins 0.000 description 1
- 108091092878 Microsatellite Proteins 0.000 description 1
- 241001529936 Murinae Species 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 102000010645 MutS Proteins Human genes 0.000 description 1
- 108010038272 MutS Proteins Proteins 0.000 description 1
- 108091007491 NSP3 Papain-like protease domains Proteins 0.000 description 1
- 101100366988 Neurospora crassa (strain ATCC 24698 / 74-OR23-1A / CBS 708.71 / DSM 1257 / FGSC 987) stu-1 gene Proteins 0.000 description 1
- 101710090055 Nitric oxide synthase, endothelial Proteins 0.000 description 1
- 101710163270 Nuclease Proteins 0.000 description 1
- 108020004711 Nucleic Acid Probes Proteins 0.000 description 1
- 239000004677 Nylon Substances 0.000 description 1
- 108020005187 Oligonucleotide Probes Proteins 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 238000012408 PCR amplification Methods 0.000 description 1
- 238000010222 PCR analysis Methods 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 102000007079 Peptide Fragments Human genes 0.000 description 1
- 108010033276 Peptide Fragments Proteins 0.000 description 1
- 239000004743 Polypropylene Substances 0.000 description 1
- 239000004793 Polystyrene Substances 0.000 description 1
- 108010092799 RNA-directed DNA polymerase Proteins 0.000 description 1
- 102100025009 Ras-related GTP-binding protein C Human genes 0.000 description 1
- 206010037888 Rash pustular Diseases 0.000 description 1
- 108091006243 SLC7A13 Proteins 0.000 description 1
- 108020004682 Single-Stranded DNA Proteins 0.000 description 1
- UIIMBOGNXHQVGW-DEQYMQKBSA-M Sodium bicarbonate-14C Chemical compound [Na+].O[14C]([O-])=O UIIMBOGNXHQVGW-DEQYMQKBSA-M 0.000 description 1
- 102100023135 Solute carrier family 7 member 13 Human genes 0.000 description 1
- 102100030684 Sphingosine-1-phosphate phosphatase 1 Human genes 0.000 description 1
- 101710168942 Sphingosine-1-phosphate phosphatase 1 Proteins 0.000 description 1
- 241000282887 Suidae Species 0.000 description 1
- 241000718541 Tetragastris balsamifera Species 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 239000012190 activator Substances 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 210000004100 adrenal gland Anatomy 0.000 description 1
- 210000001943 adrenal medulla Anatomy 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 229960002478 aldosterone Drugs 0.000 description 1
- KLRSDBSKUSSCGU-KRQUFFFQSA-N aliskiren fumarate Chemical compound OC(=O)\C=C\C(O)=O.COCCCOC1=CC(C[C@@H](C[C@H](N)[C@@H](O)C[C@@H](C(C)C)C(=O)NCC(C)(C)C(N)=O)C(C)C)=CC=C1OC.COCCCOC1=CC(C[C@@H](C[C@H](N)[C@@H](O)C[C@@H](C(C)C)C(=O)NCC(C)(C)C(N)=O)C(C)C)=CC=C1OC KLRSDBSKUSSCGU-KRQUFFFQSA-N 0.000 description 1
- WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 description 1
- 235000019418 amylase Nutrition 0.000 description 1
- 229940025131 amylases Drugs 0.000 description 1
- 229940044094 angiotensin-converting-enzyme inhibitor Drugs 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 239000005557 antagonist Substances 0.000 description 1
- 229940127088 antihypertensive drug Drugs 0.000 description 1
- 230000004872 arterial blood pressure Effects 0.000 description 1
- 238000013473 artificial intelligence Methods 0.000 description 1
- 238000013528 artificial neural network Methods 0.000 description 1
- 210000003719 b-lymphocyte Anatomy 0.000 description 1
- 239000011324 bead Substances 0.000 description 1
- 230000008033 biological extinction Effects 0.000 description 1
- 239000013060 biological fluid Substances 0.000 description 1
- 238000001574 biopsy Methods 0.000 description 1
- 235000020958 biotin Nutrition 0.000 description 1
- 238000004159 blood analysis Methods 0.000 description 1
- 230000004531 blood pressure lowering effect Effects 0.000 description 1
- 238000010804 cDNA synthesis Methods 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 150000003943 catecholamines Chemical class 0.000 description 1
- 230000022131 cell cycle Effects 0.000 description 1
- 230000003915 cell function Effects 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 210000001175 cerebrospinal fluid Anatomy 0.000 description 1
- 238000007385 chemical modification Methods 0.000 description 1
- 238000004891 communication Methods 0.000 description 1
- 238000012790 confirmation Methods 0.000 description 1
- 239000013068 control sample Substances 0.000 description 1
- 238000012937 correction Methods 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- 230000002380 cytological effect Effects 0.000 description 1
- 238000000354 decomposition reaction Methods 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 238000012217 deletion Methods 0.000 description 1
- 230000037430 deletion Effects 0.000 description 1
- XPPKVPWEQAFLFU-UHFFFAOYSA-J diphosphate(4-) Chemical compound [O-]P([O-])(=O)OP([O-])([O-])=O XPPKVPWEQAFLFU-UHFFFAOYSA-J 0.000 description 1
- 235000011180 diphosphates Nutrition 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 238000007876 drug discovery Methods 0.000 description 1
- 238000002651 drug therapy Methods 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 210000002889 endothelial cell Anatomy 0.000 description 1
- 238000001976 enzyme digestion Methods 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 238000002875 fluorescence polarization Methods 0.000 description 1
- 238000013467 fragmentation Methods 0.000 description 1
- 238000006062 fragmentation reaction Methods 0.000 description 1
- 230000005714 functional activity Effects 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 208000016361 genetic disease Diseases 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 230000013595 glycosylation Effects 0.000 description 1
- 238000006206 glycosylation reaction Methods 0.000 description 1
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 1
- 239000010931 gold Substances 0.000 description 1
- 229910052737 gold Inorganic materials 0.000 description 1
- 235000009424 haa Nutrition 0.000 description 1
- 150000002402 hexoses Chemical class 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 230000013632 homeostatic process Effects 0.000 description 1
- 210000004408 hybridoma Anatomy 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 238000003018 immunoassay Methods 0.000 description 1
- 238000010166 immunofluorescence Methods 0.000 description 1
- 238000003364 immunohistochemistry Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 239000003049 inorganic solvent Substances 0.000 description 1
- 229910001867 inorganic solvent Inorganic materials 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 229940082094 irbesartan 150 mg Drugs 0.000 description 1
- 229940082099 irbesartan 300 mg Drugs 0.000 description 1
- SZVJSHCCFOBDDC-UHFFFAOYSA-N iron(II,III) oxide Inorganic materials O=[Fe]O[Fe]O[Fe]=O SZVJSHCCFOBDDC-UHFFFAOYSA-N 0.000 description 1
- 238000001155 isoelectric focusing Methods 0.000 description 1
- 108010045069 keyhole-limpet hemocyanin Proteins 0.000 description 1
- 238000009533 lab test Methods 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 210000002751 lymph Anatomy 0.000 description 1
- 238000010841 mRNA extraction Methods 0.000 description 1
- 108010026228 mRNA guanylyltransferase Proteins 0.000 description 1
- 229920002521 macromolecule Polymers 0.000 description 1
- 241001515942 marmosets Species 0.000 description 1
- 230000000873 masking effect Effects 0.000 description 1
- 238000013178 mathematical model Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 235000010755 mineral Nutrition 0.000 description 1
- 230000009149 molecular binding Effects 0.000 description 1
- 238000002703 mutagenesis Methods 0.000 description 1
- 231100000350 mutagenesis Toxicity 0.000 description 1
- 239000006225 natural substrate Substances 0.000 description 1
- 210000001640 nerve ending Anatomy 0.000 description 1
- 238000003499 nucleic acid array Methods 0.000 description 1
- 238000007899 nucleic acid hybridization Methods 0.000 description 1
- 239000002853 nucleic acid probe Substances 0.000 description 1
- 229920001778 nylon Polymers 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 239000002751 oligonucleotide probe Substances 0.000 description 1
- 238000011275 oncology therapy Methods 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 239000000123 paper Substances 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 150000002972 pentoses Chemical class 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 229920003023 plastic Polymers 0.000 description 1
- 229920001983 poloxamer Polymers 0.000 description 1
- 229920002401 polyacrylamide Polymers 0.000 description 1
- 229920000447 polyanionic polymer Polymers 0.000 description 1
- 229920000573 polyethylene Polymers 0.000 description 1
- 229920005862 polyol Polymers 0.000 description 1
- 150000003077 polyols Chemical class 0.000 description 1
- 229920001155 polypropylene Polymers 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 229920002223 polystyrene Polymers 0.000 description 1
- 230000001323 posttranslational effect Effects 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 230000009290 primary effect Effects 0.000 description 1
- 239000002987 primer (paints) Substances 0.000 description 1
- 238000004393 prognosis Methods 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 230000004853 protein function Effects 0.000 description 1
- 238000000164 protein isolation Methods 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 208000029561 pustule Diseases 0.000 description 1
- 238000012175 pyrosequencing Methods 0.000 description 1
- 238000011002 quantification Methods 0.000 description 1
- 238000009790 rate-determining step (RDS) Methods 0.000 description 1
- 230000009103 reabsorption Effects 0.000 description 1
- 239000011541 reaction mixture Substances 0.000 description 1
- 230000009257 reactivity Effects 0.000 description 1
- 238000004153 renaturation Methods 0.000 description 1
- 229940108461 rennet Drugs 0.000 description 1
- 108010058314 rennet Proteins 0.000 description 1
- 238000012107 replication analysis Methods 0.000 description 1
- 108091008146 restriction endonucleases Proteins 0.000 description 1
- 238000003757 reverse transcription PCR Methods 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 102200087998 rs8187710 Human genes 0.000 description 1
- 210000003296 saliva Anatomy 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 210000000582 semen Anatomy 0.000 description 1
- 238000009589 serological test Methods 0.000 description 1
- 230000011664 signaling Effects 0.000 description 1
- 239000010703 silicon Substances 0.000 description 1
- 229910052710 silicon Inorganic materials 0.000 description 1
- 150000003384 small molecules Chemical class 0.000 description 1
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 1
- 239000007790 solid phase Substances 0.000 description 1
- 230000000392 somatic effect Effects 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 210000004243 sweat Anatomy 0.000 description 1
- 210000002820 sympathetic nervous system Anatomy 0.000 description 1
- 210000001138 tear Anatomy 0.000 description 1
- 238000001269 time-of-flight mass spectrometry Methods 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 238000011269 treatment regimen Methods 0.000 description 1
- 238000000539 two dimensional gel electrophoresis Methods 0.000 description 1
- 238000011144 upstream manufacturing Methods 0.000 description 1
- 238000010200 validation analysis Methods 0.000 description 1
- 229940102035 valsartan 160 mg Drugs 0.000 description 1
- 229940102034 valsartan 80 mg Drugs 0.000 description 1
- 238000009834 vaporization Methods 0.000 description 1
- 230000008016 vaporization Effects 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- 210000005166 vasculature Anatomy 0.000 description 1
- 238000012800 visualization Methods 0.000 description 1
- 239000002023 wood Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/156—Polymorphic or mutational markers
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/172—Haplotypes
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Engineering & Computer Science (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Analytical Chemistry (AREA)
- Genetics & Genomics (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pathology (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- General Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Physics & Mathematics (AREA)
- Biophysics (AREA)
- Biotechnology (AREA)
- Immunology (AREA)
- Microbiology (AREA)
- General Chemical & Material Sciences (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US66424805P | 2005-03-22 | 2005-03-22 | |
| US74240106P | 2006-02-06 | 2006-02-06 | |
| PCT/US2006/009913 WO2006102177A2 (en) | 2005-03-22 | 2006-03-20 | Biomarkers for efficacy of aliskiren as a hypertensive agent |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2007011697A true MX2007011697A (es) | 2007-11-16 |
Family
ID=37024459
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2007011697A MX2007011697A (es) | 2005-03-22 | 2006-03-20 | Biomarcadores para eficacia de aliskiren como agente hipertensivo. |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US20100240760A1 (enExample) |
| JP (1) | JP2008538549A (enExample) |
| KR (1) | KR20080005926A (enExample) |
| AU (1) | AU2006227283B2 (enExample) |
| BR (1) | BRPI0609702A2 (enExample) |
| CA (1) | CA2600525A1 (enExample) |
| MX (1) | MX2007011697A (enExample) |
| WO (1) | WO2006102177A2 (enExample) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BRPI0609702A2 (pt) * | 2005-03-22 | 2010-04-20 | Novartis Ag | biomarcadores para a eficácia de aliskiren como um agente hipertensivo |
| PT2205279E (pt) * | 2007-09-28 | 2011-07-11 | Novartis Ag | Associação farmacêutica de aliscireno e valsartan |
| CN108660205A (zh) * | 2018-07-04 | 2018-10-16 | 刘城 | 一种糖尿病遗传风险评估试剂盒及其运用 |
| CN111024960B (zh) * | 2019-12-27 | 2023-02-17 | 广州阳普医疗科技股份有限公司 | 用于高血压血样检测的添加剂、试剂盒和应用 |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1988008457A1 (en) * | 1987-04-30 | 1988-11-03 | Biotechnology Research Partners, Ltd. | Hypertension-related blood tests useful as genetic markers |
| WO2000022166A2 (en) * | 1998-10-14 | 2000-04-20 | Pyrosequencing Ab | Genes for assessing cardiovascular status and compositions for use thereof |
| PL219032B1 (pl) * | 2002-05-17 | 2015-03-31 | Novartis Ag | Kompozycja farmaceutyczna zawierająca alskiren, amlodypinę i hydrochlortiazyd, kombinacja zawierająca te składniki, zastosowanie wspomnianej kombinacji oraz zestaw handlowy zawierający wspomnianą kombinację |
| US8304190B2 (en) * | 2005-02-02 | 2012-11-06 | Royal College Of Surgeons In Ireland | Pharmacogenomics of blood pressure lowering agents |
| BRPI0609702A2 (pt) * | 2005-03-22 | 2010-04-20 | Novartis Ag | biomarcadores para a eficácia de aliskiren como um agente hipertensivo |
-
2006
- 2006-03-20 BR BRPI0609702-2A patent/BRPI0609702A2/pt not_active IP Right Cessation
- 2006-03-20 JP JP2008503059A patent/JP2008538549A/ja active Pending
- 2006-03-20 CA CA002600525A patent/CA2600525A1/en not_active Abandoned
- 2006-03-20 US US11/909,202 patent/US20100240760A1/en not_active Abandoned
- 2006-03-20 AU AU2006227283A patent/AU2006227283B2/en not_active Ceased
- 2006-03-20 WO PCT/US2006/009913 patent/WO2006102177A2/en not_active Ceased
- 2006-03-20 KR KR1020077024124A patent/KR20080005926A/ko not_active Ceased
- 2006-03-20 MX MX2007011697A patent/MX2007011697A/es active IP Right Grant
Also Published As
| Publication number | Publication date |
|---|---|
| BRPI0609702A2 (pt) | 2010-04-20 |
| AU2006227283B2 (en) | 2010-07-01 |
| WO2006102177A2 (en) | 2006-09-28 |
| US20100240760A1 (en) | 2010-09-23 |
| JP2008538549A (ja) | 2008-10-30 |
| WO2006102177A3 (en) | 2007-05-10 |
| KR20080005926A (ko) | 2008-01-15 |
| CA2600525A1 (en) | 2006-09-28 |
| AU2006227283A1 (en) | 2006-09-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20100035251A1 (en) | BioMarkers for the Progression of Alzheimer's Disease | |
| US20100249107A1 (en) | Biomarkers for Alzheimer's Disease Progression | |
| US20070065821A1 (en) | Methods for the prediction of suicidality during treatment | |
| WO2006104812A2 (en) | Biomarkers for pharmacogenetic diagnosis of type 2 diabetes | |
| AU2006227283B2 (en) | Biomarkers for efficacy of aliskiren as a hypertensive agent | |
| WO2006060429A2 (en) | Identification of variants in histone deacetylase 1 (hdac1) to predict drug response | |
| RU2408363C2 (ru) | Биомаркеры для оценки эффективности алискирена в качестве гипертензивного агента | |
| WO2006110478A2 (en) | Mutations and polymorphisms of epidermal growth factor receptor | |
| US20090281090A1 (en) | Biomarkers for the prediction of responsiveness to clozapine treatment | |
| US20050250118A1 (en) | EPHX2 Genetic markers associated with galantamine | |
| US20060178843A1 (en) | Genetic markers in the CSF2RB gene associated with an adverse hematological response to drugs | |
| US20050255495A1 (en) | SLC5A7 genetic markers associated with age of onset of Alzheimer's disease | |
| WO2007109183A2 (en) | Mutations and polymorphisms of fms-related tyrosine kinase 1 | |
| AU2004269323A1 (en) | CHRNA2 genetic markers associated with galantamine response | |
| CN101146915A (zh) | 高血压药阿利克仑功效的生物标志物 | |
| WO2007002217A2 (en) | Mutations and polymorphisms of bcl-2 | |
| WO2007121017A2 (en) | Mutations and polymorphisms of fms-like tyrosine kinase 4 | |
| WO2007058991A2 (en) | Mutations and polymorphisms of c-abl |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Grant or registration |